These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 25829274)
1. Anticancer drugs: On-site CAR parking. Bray N Nat Rev Drug Discov; 2015 Apr; 14(4):235. PubMed ID: 25829274 [No Abstract] [Full Text] [Related]
2. Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care. Riccione K; Suryadevara CM; Snyder D; Cui X; Sampson JH; Sanchez-Perez L J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741761 [TBL] [Abstract][Full Text] [Related]
3. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma. Ren PP; Li M; Li TF; Han SY Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023 [TBL] [Abstract][Full Text] [Related]
4. CAR T Cells Infiltrate Brain, Target Tumors. Cancer Discov; 2017 Sep; 7(9):926. PubMed ID: 28754782 [TBL] [Abstract][Full Text] [Related]
5. Targeting EGFRvIII for glioblastoma multiforme. Yang J; Yan J; Liu B Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003 [TBL] [Abstract][Full Text] [Related]
6. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells. Murakami T; Nakazawa T; Natsume A; Nishimura F; Nakamura M; Matsuda R; Omoto K; Tanaka Y; Shida Y; Park YS; Motoyama Y; Nakagawa I; Yamada S; Tamura K; Takeshima Y; Takamura Y; Wakabayashi T; Nakase H Anticancer Res; 2018 Sep; 38(9):5049-5056. PubMed ID: 30194149 [TBL] [Abstract][Full Text] [Related]
7. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190 [TBL] [Abstract][Full Text] [Related]
8. Novel mechanisms and approaches in immunotherapy for brain tumors. Finocchiaro G; Pellegatta S Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082 [TBL] [Abstract][Full Text] [Related]
9. How fine a slice: treatment of newly diagnosed glioblastoma with an epidermal growth factor receptor variant III peptide vaccine. Chamberlain MC J Clin Oncol; 2011 Jun; 29(17):e517-8; author reply e519-20. PubMed ID: 21555685 [No Abstract] [Full Text] [Related]
10. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. Caruso HG; Torikai H; Zhang L; Maiti S; Dai J; Do KA; Singh H; Huls H; Lee DA; Champlin RE; Heimberger AB; Cooper LJ J Immunother; 2016 Jun; 39(5):205-17. PubMed ID: 27163741 [TBL] [Abstract][Full Text] [Related]
11. Updates On Chimeric Antigen Receptor-Mediated Glioblastoma Immunotherapy. Mao G; Sampath P; Sengupta S R I Med J (2013); 2017 Jun; 100(6):39-42. PubMed ID: 28564668 [TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy in brain tumors]. De Carli E; Delion M; Rousseau A Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040 [TBL] [Abstract][Full Text] [Related]
14. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses. Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624 [TBL] [Abstract][Full Text] [Related]
15. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245 [TBL] [Abstract][Full Text] [Related]
16. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants. Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091 [TBL] [Abstract][Full Text] [Related]
17. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering. Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559 [TBL] [Abstract][Full Text] [Related]
18. Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging. Liu K; Liu X; Peng Z; Sun H; Zhang M; Zhang J; Liu S; Hao L; Lu G; Zheng K; Gong X; Wu D; Wang F; Shen L Oncotarget; 2015 Sep; 6(27):23735-47. PubMed ID: 26124178 [TBL] [Abstract][Full Text] [Related]
19. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme. Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269 [TBL] [Abstract][Full Text] [Related]
20. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]